GALT
Galectin Therapeutics Inc. NASDAQ Listed Sep 4, 2002$4.23
+7.91%
vs $3.92
Mkt Cap $270.3M
52w Low $2.08
48.5% of range
52w High $6.51
50d MA $2.48
200d MA $3.72
P/E (TTM)
-10.4x
EV/EBITDA
—
P/B
—
Debt/Equity
-1.1x
ROE
24.1%
P/FCF
-11.3x
RSI (14)
92.60
ATR (14)
$0.32
Beta
1.04
50d MA
$2.48
200d MA
$3.72
Avg Volume
545.9K
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
4960 Peachtree Industrial Boulevard · Norcross, GA 30071 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -0.10 | -0.08 | +20.0% | 2.79 | -0.4% | -3.9% | -0.4% | -4.1% | -14.5% | +1.4% | — |
| Nov 14, 2025 | AMC | -0.11 | -0.13 | -18.2% | 5.51 | +1.8% | +8.9% | +3.2% | -7.3% | +0.0% | -6.8% | — |
| Aug 14, 2025 | AMC | -0.16 | -0.12 | +25.0% | 3.76 | +0.8% | -5.1% | +9.2% | -3.8% | +4.0% | -0.5% | — |
| May 15, 2025 | AMC | -0.20 | -0.15 | +25.0% | 1.32 | -1.5% | -3.0% | +3.9% | -3.0% | -0.8% | +0.0% | — |
| Mar 31, 2025 | AMC | -0.16 | -0.19 | -18.8% | 1.22 | +0.0% | +3.3% | +4.8% | -3.0% | +3.1% | +0.8% | — |
| Nov 14, 2024 | AMC | -0.20 | -0.18 | +10.0% | 2.75 | +1.8% | +0.7% | -2.9% | +2.6% | +2.2% | -3.5% | — |
| Aug 13, 2024 | AMC | -0.16 | -0.20 | -25.0% | 2.25 | -1.3% | -7.6% | +5.3% | +5.9% | +1.3% | -2.1% | — |
| May 15, 2024 | AMC | -0.16 | -0.19 | -18.8% | 3.06 | +0.3% | +2.6% | +2.9% | -2.2% | +2.2% | -3.7% | — |
| Mar 29, 2024 | AMC | -0.16 | -0.16 | +0.0% | — | — | — | — | — | — | — | — |
| Nov 13, 2023 | AMC | -0.16 | -0.24 | -50.0% | 1.95 | +0.0% | -7.2% | +3.3% | +1.1% | +3.7% | -4.6% | — |
| Aug 14, 2023 | AMC | -0.21 | -0.15 | +28.6% | 1.49 | -1.3% | +7.4% | -1.9% | +10.2% | -6.9% | +0.6% | — |
| May 15, 2023 | AMC | -0.21 | -0.19 | +9.5% | 1.64 | +1.2% | -1.2% | +3.1% | -1.5% | +6.4% | +4.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.20 | $6.57 | +6.0% | +4.4% | -4.8% | -28.9% | -8.0% | -1.0% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.67 | $3.69 | +0.5% | +2.5% | -5.1% | +9.2% | -3.8% | +4.0% |
| Apr 2 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.26 | $1.23 | -2.4% | +4.8% | -3.0% | +3.1% | +0.8% | -4.5% |
| Dec 27 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $0.87 | $0.90 | +3.6% | +32.2% | -4.3% | +17.3% | -9.3% | -0.9% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.75 | $2.80 | +1.8% | +0.7% | -2.9% | +2.6% | +2.2% | -3.5% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.19 | $2.18 | -0.5% | +5.9% | +1.3% | -2.1% | +1.3% | -0.9% |
| Apr 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.74 | $3.74 | +0.0% | +5.3% | -3.0% | +9.9% | -5.5% | -1.5% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.39 | $2.39 | +0.0% | +2.1% | +2.9% | +13.5% | +5.3% | +24.3% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.49 | $1.47 | -1.3% | +7.4% | -1.9% | +10.2% | -6.9% | +0.6% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.62 | $1.63 | +0.6% | +3.1% | -1.5% | +6.4% | +4.0% | -1.1% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.22 | $2.25 | +1.4% | +8.1% | -9.6% | -1.4% | -3.7% | +1.9% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.26 | $1.39 | +10.3% | +7.1% | -5.2% | +3.1% | -3.0% | +3.1% |
| Apr 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.23 | $2.27 | +1.8% | -1.8% | +26.9% | -2.9% | +9.3% | +17.3% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.61 | $2.71 | +3.8% | +10.0% | +7.0% | -0.7% | -4.3% | +5.5% |
| Apr 3 | B. Riley Securities | Maintains | Buy → Buy | — | $1.66 | $1.65 | -0.6% | +3.6% | +6.4% | -6.0% | +1.7% | +4.9% |
| Apr 3 | B. Riley FBR | Maintains | Buy → Buy | — | $1.66 | $1.65 | -0.6% | +3.6% | +6.4% | -6.0% | +1.7% | +4.9% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.66 | $1.70 | +2.4% | +4.8% | -13.2% | +9.3% | +6.7% | -2.3% |
| Feb 13 | B. Riley FBR | Maintains | Buy → Buy | — | $4.46 | $4.78 | +7.2% | +3.4% | +7.8% | +3.0% | +1.6% | +14.8% |
| Oct 19 | Roth Capital | Maintains | Buy → Buy | — | $2.51 | $2.60 | +3.6% | -0.8% | +6.8% | -4.5% | +3.5% | -1.1% |
| Oct 6 | Seaport Global | Maintains | Buy → Buy | — | $2.43 | $2.54 | +4.5% | +0.4% | +7.0% | +6.5% | -0.7% | -1.1% |
| Mar 30 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $1.98 | $2.16 | +9.1% | +2.5% | +13.3% | -5.2% | -1.8% | +0.5% |
| Mar 30 | H.C. Wainwright | Upgrade | Neutral → Buy | — | $1.98 | $2.16 | +9.1% | +2.5% | +13.3% | -5.2% | -1.8% | +0.5% |
| Oct 3 | FBR Capital | Downgrade | Outperform → Market Perform | — | $1.13 | $1.12 | -0.9% | +1.8% | -3.5% | -4.5% | -4.7% | -6.1% |
| Sep 29 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $1.40 | $1.33 | -5.0% | -12.9% | -7.4% | +1.8% | -3.5% | -4.5% |
| Sep 29 | H.C. Wainwright | Downgrade | Buy → Neutral | — | $1.40 | $1.33 | -5.0% | -12.9% | -7.4% | +1.8% | -3.5% | -4.5% |
| Sep 28 | Roth Capital | Downgrade | Buy → Sell | — | $2.47 | $1.20 | -51.4% | -43.3% | -12.9% | -7.4% | +1.8% | -3.5% |
| Sep 21 | H.C. Wainwright | Maintains | Buy → Buy | — | $2.28 | $2.40 | +5.3% | +5.3% | -2.9% | -0.9% | -1.7% | -6.2% |
| Aug 1 | Aegis Capital | Downgrade | Buy → Hold | — | $6.14 | $5.98 | -2.6% | -7.3% | -6.3% | +5.1% | -0.7% | -1.6% |
| Apr 2 | McNicoll Lewis Vlak | Maintains | Buy → Buy | — | $13.58 | $13.65 | +0.5% | +3.4% | -5.6% | -7.8% | -2.2% | +0.9% |
| Feb 12 | Aegis Capital | Maintains | Buy → Buy | — | $15.46 | $15.70 | +1.6% | +4.6% | -1.1% | -7.3% | +4.3% | -1.3% |
| Oct 7 | Ascendiant Capital | Maintains | Buy → Buy | — | $11.00 | $11.13 | +1.2% | +9.6% | -7.9% | -8.0% | +9.5% | -0.4% |
| Jul 25 | Aegis Capital | Maintains | Buy → Buy | — | $2.48 | $2.82 | +13.7% | +13.7% | -8.9% | +5.0% | -5.9% | -7.9% |
| Jul 6 | Dawson James | Maintains | Buy → Buy | — | $1.89 | $1.75 | -7.4% | -1.6% | +3.2% | -3.7% | -0.5% | +0.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 23, 2026 | Jamil Khurram | Chief Medical Officer | Sell | 7,557 | $3.14 | $24K | — | — | — |
| May 26, 2026 | Jamil Khurram | Chief Medical Officer | Sell | 568 | $3.10 | $2K | — | -1.95% | +1.28% |
8-K · 7.01
! Medium
Galectin Therapeutics Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 23
8-K · 2.02
!! High
Galectin Therapeutics Inc. -- 8-K 2.02: Earnings Results
May 15
8-K
Unknown — 8-K Filing
Galectin Therapeutics is furnishing supplementary risk disclosure without formal SEC filing, suggesting potential material developments that warrant investor review of the complete 10-K filing for full context.
Mar 31
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Loss of a highly accomplished neurosurgery expert with 40+ years of NIH funding and 416 publications weakens GALT's scientific credibility and innovation pipeline in its core brain tumor treatment business.
Mar 17
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 1,966,542 | $5M | New | Mar 2026 |
| 2 | Marshall Wace, Llp | 1,219,912 | $3M | Added | Mar 2026 |
| 3 | Morgan Stanley | 558,576 | $2M | Added | Dec 2025 |
| 4 | Millennium Management | 798,434 | $2M | Added | Mar 2026 |
| 5 | Wealthspire Advisors, Llc | 721,788 | $2M | Added | Mar 2026 |
| 6 | Susquehanna International Group, Llp | 555,702 | $2M | Added | Mar 2026 |
| 7 | Commonwealth Equity Services, Llc | 334,096 | $1M | Added | Dec 2025 |
| 8 | Two Sigma Investments, Lp | 467,063 | $1M | Added | Mar 2026 |
| 9 | Jane Street Group, Llc | 199,339 | $829K | Added | Dec 2025 |
| 10 | Citadel Advisors Llc | 290,360 | $810K | New | Mar 2026 |
| 11 | Vivaldi Capital Management Lp | 258,584 | $721K | Added | Mar 2026 |
| 12 | Geneos Wealth Management Inc. | 240,927 | $672K | Reduced | Mar 2026 |
| 13 | Ubs Group Ag | 179,741 | $501K | Added | Mar 2026 |
| 14 | Fortis Capital Advisors, Llc | 106,139 | $442K | New | Dec 2025 |
| 15 | Blair William & Co/il | 149,283 | $416K | Added | Mar 2026 |
| 16 | Renaissance Technologies Llc | 147,900 | $413K | New | Mar 2026 |
| 17 | Hightower Advisors, Llc | 88,375 | $368K | — | Dec 2025 |
| 18 | Northern Trust Corp | 130,448 | $364K | — | Mar 2026 |
| 19 | Qube Research & Technologies Ltd | 126,439 | $353K | Added | Mar 2026 |
| 20 | Hudson Bay Capital Management Lp | 78,145 | $325K | Added | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 10
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 276,536 | $824K | Feb 2026 |
| 2 | iShares Micro-Cap ETF | 114,442 | $319K | Mar 2026 |
| 3 | Fidelity Total Market Index Fund | 95,489 | $285K | Feb 2026 |
| 4 | Fidelity Series Total Market Index Fund | 74,000 | $221K | Feb 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 45,615 | $136K | Feb 2026 |
| 6 | Schwab Total Stock Market Index Fund | 29,970 | $85K | Jan 2026 |
| 7 | Invesco NASDAQ Future Gen 200 ETF | 11,563 | $34K | Feb 2026 |
| 8 | Small Cap Core Fund | 5,380 | $15K | Mar 2026 |
| 9 | Victory Extended Market Index Fund | 4,772 | $14K | Jan 2026 |
| 10 | Knights of Columbus U.S. ALL CAP INDEX FUND | 232 | $657 | Jan 2026 |
Valuation
Market Cap
$270.3M
Enterprise Value
$386.3M
P/E (TTM)
-10.39x
Forward P/E
—
PEG Ratio
0.23x
P/B
—
P/S
—
P/FCF
-11.32x
EV/EBITDA
—
Shares Out
63.9M
Financials (TTM)
Revenue
$0
Net Income
-$26.3M
EBITDA
-$18.6M
Free Cash Flow
-$23.9M
Op Cash Flow
-$23.9M
EPS Basic
$-0.48
EPS Diluted
$-0.41
EPS Forward
$-0.31
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$19.5M
Total Liab.
$145.7M
Total Equity
-$126.2M
Cash
$17.7M
LT Debt
$133.7M
Book Value/Sh
$-1.97
Debt/Equity
-1.06x
Current Ratio
2.42
Quick Ratio
2.42
Returns & Growth
ROE
24.1%
ROA
-157.9%
ROIC
-174.3%
Rev Growth YoY
+0.0%
EPS Growth YoY
+36.8%
Price Returns
2W
+7.2%
1M
+11.0%
3M
-15.4%
6M
-56.0%
12M
+92.4%
Technicals
52W High
$6.51
52W Low
$2.08
50d MA
$2.48
200d MA
$3.72
RSI (14)
92.60
ATR (14)
$0.32
Beta
1.04
Avg Volume
546K
Dividends
Div Rate
$0.00
Div Yield
0.1%
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$11.00
High
$11.00
Low
$11.00
Median
$11.00
Data updated apr 25, 2026 10:39am
· Source: financialmodelingprep.com